Details of the Drug Excipient | DrugMAP

General Information of Drug Inactive Ingredient (DIG) (ID: E00324)

DIG Name	Erythrosine sodium anhydrous
Synonyms	Erythrosine sodium; 568-63-8; TIF Na; CHEBI:61000; disodium 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate; Erythrosin B sodium salt (C.I. 45430); Erythrosine (Free Acid); DSSTox_CID_1233; DSSTox_RID_76025; DSSTox_GSID_21233; disodium;2-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate; CAS-16423-68-0; 2-(6-hydroxy-2,4,5,7-tetraiodo-3-oxoxanthen-9-yl)benzoic acid, sodium salt, so dium salt; NSC 36685; ERYTHROSINE SODIUM (OPEN FORM); Erythrosine sodium (open form) [USAN]; Iodoeosine Sodium Salt; FD & C red no. 3; SCHEMBL22294; CHEMBL2028187; DTXSID901015598; HMS3264L03; Tox21_202932; Tox21_302085; SBB058454; STL445510; AKOS001028625; AKOS015903534; CCG-213542; MCULE-6568431757; Benzoic acid, 2-(6-hydroxy-2,4,5,7-tetraiodo-3-oxo-3H-xanthen-9-yl)-, disodium salt; NCGC00255371-01; NCGC00260478-01; C.I.45430; F0139; ST50411609; ACID RED 51 (ERYTHROSIN B C.I. 45430); Erythrosin B sodium salt (C.I. 45430), certified; W-107946; Q27888290; Z56758124; UNII-B16H36W4W4 component IINNWAYUJNWZRM-UHFFFAOYSA-L; Disodium 2-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl) benzoate; disodium 2-(2,4,5,7-tetraiodo-6-oxido-3-oxo-8a,10a-dihydro-3H-xanthen-9-yl)benzoate; Fluorescein, 2',4',5',7'-tetraiodo-, disodium salt (Benzoic acid tautomeric form)
DIG Function	Colorant
Formula	C20H6I4Na2O5
Canonical SMILES	C1=CC=C(C(=C1)C2=C3C=C(C(=O)C(=C3OC4=C(C(=C(C=C24)I)[O-])I)I)I)C(=O)[O-].[Na+].[Na+]
InChI	1S/C20H8I4O5.2Na/c21-11-5-9-13(7-3-1-2-4-8(7)20(27)28)10-6-12(22)17(26)15(24)19(10)29-18(9)14(23)16(11)25;;/h1-6,25H,(H,27,28);;/q;2*+1/p-2
InChIKey	IINNWAYUJNWZRM-UHFFFAOYSA-L
Physicochemical Properties	Molecular Weight		879.9	Topological Polar Surface Area	89.5
	XlogP		N.A.	Complexity	797
	Heavy Atom Count		31	Rotatable Bond Count	1
	Hydrogen Bond Donor Count		0	Hydrogen Bond Acceptor Count	5

Full List of Drug(s) Co-administrated with This DIG

10 Approved Drug(s) Co-administrated with This DIG

Drug Name	Drug ID	Indication	Formulation Name	Formulation ID
Cariprazine	DMJYDVK	Bipolar disorder [6A60]	Cariprazine Hydrochloride eq 6mg base capsule	F23397
Cinoxacin	DM4EWNS	Urinary tract infection [GC08]	Cinoxacin 250mg capsule	F23115
Disopyramide	DM5SYZP	Long QT syndrome [BC65.0]	Disopyramide Phosphate eq 150mg base capsule	F23424
Meclofenamate Sodium	DMNL98G	Arthritis [FA20]	Meclofenamate Sodium eq 50mg base capsule	F23225
Naltrexone	DMUL45H	Alcohol dependence [6C40.2]	Naltrexone Hydrochloride 0.8mg extended release capsule	F24301
Opicapone	DM1BKA6	Parkinson disease [8A00.0]	Opicapone 50 mg capsule	F23846
Stiripentol	DMMSDOY	Dravet syndrome [8A61.11]	Stiripentol 250 mg powder	F24373
Tasimelteon	DMLOQ1V	Insomnia [7A00-7A0Z]	Tasimelteon 20mg capsule	F23915
Tecovirimat	DMW5ML9	Smallpox [1E70]	Tecovirimat 200 mg capsule	F23301
Tolmetin	DMWUIJE	Osteoarthritis [FA00-FA05]	Tolmetin Sodium eq 400mg base capsule	F23576
------------------


⏷ Show the Full List of 10 Approved Drug(s)

1 Clinical Trial Drug(s) Co-administrated with This DIG

Drug Name	Drug ID	Indication	Formulation Name	Formulation ID
MK-4827	DMLYGH4	Ovarian cancer [2C73]	Niraparib 100 mg capsule	F15383
------------------